Open access peer-reviewed chapter

Integrating Nanotherapeutic Platforms to Image Guided Approaches for Management of Cancer

Written By

Asad Ali, Zeeshan Ahmad, Usama Ahmad, Mohd Muazzam Khan, Md. Faheem Haider and Juber Akhtar

Submitted: August 19th, 2020 Reviewed: October 8th, 2020 Published: October 27th, 2020

DOI: 10.5772/intechopen.94391

Chapter metrics overview

449 Chapter Downloads

View Full Metrics


Cancer is a leading cause of mortality worldwide, accounting for 8.8 million deaths in 2015. The landscape of cancer therapeutics is rapidly advancing with development of new and sophisticated approaches to diagnostic testing. Treatment plan for early diagnosed patients include radiation therapy, tumor ablation, surgery, immunotherapy and chemotherapy. However the treatment can only be initiated when the cancer has been diagnosed thoroughly. Theranostics is a term that combines diagnostics with therapeutics. It embraces multiple techniques to arrive at comprehensive diagnosis, molecular images and an individualized treatment regimen. Recently, there is an effort to tangle the emerging approach with nanotechnologies, in an attempt to develop theranostic nanoplatforms and methodologies. Theranostic approach to management of cancer offers numerous advantages. They are designed to monitor cancer treatment in real time. A wide variety of theranostic nanoplatforms that are based on diverse nanostructures like magnetic nanoparticles, carbon nanotubes, gold nanomaterials, polymeric nanoparticles and silica nanoparticles showed great potential as cancer theranostics. Nano therapeutic platforms have been successful in integrating image guidance with targeted approach to treat cancer.


  • nanomedicine
  • theranostics
  • targeted delivery
  • cancer
  • functionalized nanomedicine

1. Introduction

Cancer has a major impact on society across the world. Estimated number of new cases of cancer, current cases of cancer, deaths, survival rate, mortality and in depth information, symptoms of cancer, its early detection, prevention and treatment all are provided by American Cancer Society. Nearly 13% of cancer diagnosed in 2017 was in the young at age of 20. The new review statistics shows 28 types of rare cancer which talks about mortality rate, survival, diagnosis and also provides an idea about symptoms and risk factors related to different types of cancer [1].

Therapeutic approaches such as development of nanoemulsions, liposomes, microspheres and nanoparticles have facilitated in fighting cancer. Among these, the simplest platforms are the nanoemulsion having size range of 100 to 500 nm which are kinetically stabilized having high content of oil and low amount of surfactant [2]. Solubility of poorly soluble drugs [3, 4] and its bioavailability can be increased by converting the drug into forms like capsule and gels [5] or can be used in their original form. The method used for the fabrication of nanoemulsion are high energy methods (microfluidization and sonication) and low energy emulsification method [6, 7, 8].

Theranostics is a term originally coined to define an approach that combine’s diagnostics with therapeutics [9]. It embraces multiple techniques to arrive at comprehensive diagnosis, molecular images and an individualized treatment regimen [10, 11]. Recently, there is an effort to tangle the emerging approach with nanotechnologies, in an attempt to develop theranostic nanoplatforms and methodologies [12]. Given that cancer is a highly heterogeneous and adaptable disease, diverse types of treatment options need to be chosen depending on patient’s characteristics and disease progression.


2. Theranostics

Drugs or methods that are used for accompanying diagnosis and cure [13] are referred to as Theranostics. One of the achievements of nanotechnology is the fabrication of theranostic nanomedicine for the preparation of these types of drugs. The term defines “a nanotherapeutic system which can deliver targeted therapy and diagnose”. This aspect provides help when fabricating nano based image contrasting agent and also in image guided therapeutics [14].

Rapid drug development, advanced disease management, reduced associated risk and cost are assumed to be the result of mutual techniques. Such type of investigation which involves quick diagnosis and treatment are very helpful in disease which are a major cause of morbidity and/or mortality and cancer is one of the disease and coincidently the initial research in theranostic is dedicated to oncology. Sound knowledge, core understanding of detection and therapy mechanism are required for the formation of theranostic agents. In order to fabricate theranostic agents one should have understanding of diagnostic strategies, molecular mechanism adverse effect and toxicity of material and techniques for nanoparticles preparation for therapy and diagnostic purpose.

Research in theranostics has rapidly improved in the past decade resulting into preparation of different contrast media and active ingredient with different method of preparation. Preparation of dual purpose nanoparticle system is the main aim of theranostics. Therefore it is important to put attention on all factors that influences the process, right from the preparation of nanoemulsion/nanoparticle till the removal of metabolites of the active molecules and other materials used. The factors can be the compatibility between chemicals, the condition in which the formulation is prepared, modification in formulations because of selected route of administration, the toxicity, metabolites of active ingredient, its biocompatibility and biodegradability and evaluation of pharmacodynamic and pharmacokinetic parameter and eventually the disadvantage and benefits of the process.

The basis of diagnosis in theranostics depends upon using different contrast agent during imaging. MRI is the most studied and used technique among all different imaging mechanism and a lot has been spent on research related to magnetic particles used as contrasting agent. Metals like gold, silver, iron oxide have been studied with the object of finding suitable particle for imaging with least toxicological effect. Diseased tissue and healthy tissue are differentiated in MRI by the use of these particles.

As stated one of the brutal disease is cancer and hence theranostic research has put an eye on this area. Day by day the research is going on in positive direction and much useful research has already been carried out. In order to understand the concept of diagnosis of cancer and therapy related to it the use of nanoparticle agents is in progression [27, 28]. One such example of theranostic agent is manganese oxide nanoparticle carrying drugs and contrast agents [29] and silica nanoparticle with magnetic and fluorescent tags [30]. In the past few years, combination of metal nanoparticle or shells [31, 32, 33] with magnetic components has yielded different theranostic agents for biomedical applications which are widely used. Some examples of theranostic agents are given in Table 1.

Contrast agentDrug usedApplicationsSizeZeta potentialReferences
Manganese oxidesiRNAMRI plus RNA delivery[15]
GoldDOX Diagnosistumor targeting and PTT45.97 nm and 6.3 nm−3.54 mV[16, 17, 18]
Iron oxidesiRNA, DOX, docetaxelTargeting, MRI and therapy30 nm−5 mV[19, 20, 21]
SilicaPyropheophorbide (HPPH), DOXDrug carrier, X-ray/CT imaging, Photodynamic therapy30 nm and 126 nm−39 mV[22, 23]
CNTsDNA plasmid, DOX, PTXDiagnosis, DNA and drug delivery20 nm and 120.6 nm[24, 25]
QDsDOX, MTXImaging, therapy and sensing[26]

Table 1.

Different theranostic agents used for biomedical applications.

Abbreviations: siRNA: short interfering ribonucleic acid, CNTs: carbon nanotubes, QDs: quantum dots, DOX: Doxorubicin, HPPH: 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-alpha, MTX: Methotrexate, PTX: Paclitaxel, MRI: Magnetic resonance imaging, CT: Computed topography.


3. Nano theranostics

Theranostic nanosystems comprise of platforms/nanocarriers that are used as imaging as well as therapeutic agents via a single entity. Nanotheranostic devices can be made by many types of inorganic and organic nanomaterials. Preclinical implementations make use of nanotheranostic system because they might provide a way or method of understanding many crucial aspects of drug delivery and how these systems can assist in knowing the power of personalized medicines.


4. Therapeutic agents

At present radiotherapy, surgery and chemotherapy are possible treatments for cancer patients. The purpose of the theranostic is to use these therapeutic strategies and reduce the risk associated with chemotherapy and radiotherapy and in addition to it avoid complications related to surgery and trauma. In addition, with the help of nanotechnology, theranostics may support the diversification of therapeutic approaches like PTT, PDT and immunotherapy. Here we report some of these therapeutic strategies often used in theranostics, like radiotherapy, chemotherapy, PDT, PTT and immunotherapy.


5. Chemotherapy for management of cancer

Anticancer drugs have proven beneficial in improving survival rate of cancer patients [34]. There are huge numbers of clinical anti-cancer drugs which are broadly applied to theranostics. On the basis of structure and resource of chemotherapy drugs, cancer therapeutic agents can be classified into six types: alkylating agent, antitumor antibiotic, phytogenic anticarcinogen, antimetabolites, hormone and miscellaneous anti-cancer drugs. Thermo DOX for liver cancer, Doxil for ovarian cancer therapy and Myocet for metastatic breast cancer are few cancer nanomedicines that have been approved by the FDA. Theranostic systems also make use of prodrugs like platinum (IV) prodrug to reduce the toxicity of drug and by increasing the active hits to the cells of tumors site. Due to their broad availability these prodrugs are very popular option. The UV light is transformed from NIR light by UCNP which activates the prodrugs to highly toxic platinum (II) complexes that enters the cell by endocytosis after grafted onto up converting nanoparticles (UCNP) [35]. In order to attain best therapeutic efficacy of drug delivery systems a high payload is essential. In theranostics, in order to maintain the original size and solubility in aqueous media a carrier with large pore volume and surface area are given preferences so that more therapeutic agent can be carried [36]. For example, Sorafenib with a loading ration of 28.2% can be loaded on porous silica nanoparticles and may release the therapeutic agent in sustained fashion [37]. GO, Ws2 and MoS2 are some of the popular 2-D nanomaterials that have a very high drug payload as they can bear chemotherapeutics on both sides of sheet. Some of the example of high drug payload include 118% for 7-ethyl-10-hydroxycamptothecin (SN38) and approx 239% for DOX were observed on MoS2 [38], DOX (approximately 400%) on GO [39] was also significant. Cancer cells show multidrug resistance (MDR) often when they are treated by single drug which can be overcome by employing efficient strategies of theranostics. By combining P-glycoprotein (P-gp) reversing agent with anticancer drug the hurdle of MDR can be resolved [40]. The function of P-gp reversing agent is to avoid the pumping of chemotherapeutic drugs out of cancer cells due to over expression of P-gp. One way to overcome MDR is by covering the positive change that is present on anticancer drugs. DOX alone cannot produce significant cancer effect but when it is adsorbed on the surface of polymeric nanoparticle more chance are there that cancer cell may readily uptake it and accumulate within cancer cell and produce more cytotoxicity to cancer cell. Nanocarriers loaded with combination of anticancer drugs provide synergistic effect thereby improving overall management of cancer [41, 42].


6. Photothermal therapy for management of cancer

Microwave, light irradiation or magnetic field can potentiate the effect of thermal therapy which in turn employs hyperthermia to kill cancer cells. Among all the above mentioned therapies photothermal therapy has the maximum capacity to destroy cancer cell while causing least damage to nearby healthy cells. Localized hyperthermia under light irradiation at tumor site is generated by using NIR absorbing agent in photothermal therapy [43]. In MR region an ideal PTT agent should show strong absorbance and must exhibit less fluorescence quantum yield thereby promoting efficient conversion of absorbed light energy into heat via non-radiative transition rather than fluorescence emission.

Inorganic nanoparticles and organic dyes are extensively employed as PTT agents. Examples of organic dyes include Prussian blue, IR780, ICG, IR820, Cypate, IR825. These organic dyes have an added advantage of ease of loading on nanoplatforms and ideal NIR absorbance [44]. In order to improve the photostability and targeting ability of organic dyes they are being encapsulated into nanocarriers [45]. Carbocyanine dyes namely cypate and ICG were loaded into the polymeric micelle with loading rate of 50% and 20% for cypate and ICG respectively. Upon comparing loaded theranostic polymeric micelle with carbocyanine dye alone showed marked cellular uptake and longer retention time at the site of tumor. Remarkable PTT results were observed along with increased photothermal effect and photostability of organic dyes when nanomaterials like graphene derivatives absorbing strongly in the NIR regions were employed [46]. In NIR and PTT imaging techniques both cypate and ICG can be used as theranostic agents.

Photothermal conversion efficiency will decrease in presence of high fluorescence quantum yield and fluorescence imaging is disturbed in case of low quantum yield hence there is not much surety in theranostic application of organic dyes. Apart from the organic dyes, a wide range of inorganic nanoparticles have been fabricated for theranostic applications. Inorganic nanoparticles exhibit strong photothermal conversion efficiency and NIR absorption for PTT. It encompasses customized gold nanostructure like nanoshell, nanocages, nanorods and nanotubes. On comparing the gold nanorods alone against gold nanorods coated with Pt nanodots, the latter showed significant better photothermal effect than the former [47]. And the better results were due to the presence of Pt shell in the endosomes which not only prevented the original sharp LSPR band of gold nanorods from shifting and dampening but also prevented the aggregation of gold nanorods. Carbon nanotubes [48], carbon dots [49], GO are some of the other nanomaterials that can used for PTT. GO for in-vivo PTT was used for the first time by Liu group. Further they reduced the GO to rGO which had 7 times more NIR absorption than GO hence increasing the PTT effect [50]. PTT for now might only be used for treating skin cancer and not for internal cancer because of limiting light penetration depth but its noteworthy therapeutics capacities with minimum possible side effect cannot be ignored. Further study is required to get deeper insight about how phototoxicity is caused by PTT.

Apart from PTT, hyperthermia induced magnetically is also one of the non-invasive procedures to treat cancer [51]. Dielectric constant and microwave frequency between malignant tissue and normal tissue in breast can be employed for the detection and treatment of breast cancer. Dielectric contrast is used for scattering of an illuminating microwave signal and the incident microwave produces hyperthermia thereby treating malignant tissues [52].


7. Photodynamic therapy for management of cancer

Photosensitizers (PSs) used in PDT plays a vital role in the treatment of cancer and possess enormous potential. Cytotoxic reactive oxygen species or free radicals are generated when the molecular oxygen surrounding the diseased cell reacts with the absorbed light that is being transferred by PSs under laser irradiation which finally causes cell apoptosis and damage to cancerous cells [53]. No side effects are observed from photosensitizes and generate ROS only when laser light is irradiated upon them.

PDT requires low light density to cause damage to cancer cell unlike the PTT which requires high density laser light to generate hyperthermia that can cause damage to cancer cells [54]. PDT encompasses noteworthy advantages like very less invasiveness, on repeating the therapy is show no cumulative toxicity, very less damage to immune and hemopoietic system thereby improving the overall health and contributing to quality life for the patient. An ideal PS must have following properties like triplet state formation of high quantum yield and a good amount of triplet lifetime so that interaction with ground state oxygen is possible thereby generating sufficient ROS. However many PSs does not have good tumor selectivity, good amount of photosensitivity and absorption maxima above 700 nm [55]. A distinctive NIR absorption at 700 nm was observed by the help of extra axial mob linkers in monosubstituted phthalocyanine [56] that produced 20 nm red shift of characteristic Q band. PEG functionalized iron oxide nanocluster surface when loaded with Ce6 the absorption peak of chlorine e6 (Ce6) showed red shift from 650 nm to 704 nm [57]. The energy transferred from UCNPs to PSs are able to excite the combination of PSs and UCNP’s, therefore inhibiting the growth of tumor by generation of cytotoxic singlet oxygen [58].


8. Radiation therapy for management of cancer

Radiation therapy has become an integral part to treat many sarcomas. The mechanism of action of radiation therapy is that the radiation damages strings of DNA in the nucleus of cells which stops the cell multiplication. Apart from aforementioned functions of radiation therapy, it also produces reactive oxygen therapy (ROS) which indirectly damages the tumor cell and also damages the DNA of mitochondria and other organelle of cell. In case of surgical resection, the survival could be prolonged by employing radiation therapy. However due to frequent and repeated high dose of X-ray irradiation that causes systemic side effects and resistance to radiation had been noticed in cancerous cells.

Metal nanoparticles in strong association with strong capacities of photoelectric absorbance are used as radiation dose enhancing agents. For example research shows that radio sensitization is being mediated by Gold NP due to greater energy deposition and absorption in surrounding tissue from photoelectrons. Radiotherapy with prolonged circulation time in blood has been demonstrated by Auger electrons and characteristic X-rays [59] and polyethylene glycosylation modified gold nanoparticle (N GNPs). Radiotherapy can relieve the symptoms and prolong the lives of terminal cancer patients. However radiotherapy is not an easy task and may cause loss of organ functions also as it may also induce many complications. Moreover, it cannot completely remove cancer cells. In coming future we may see highly accurate and precise exposure of tumor site to high radiation by the application of radiation wave knife for much better clinical results.


9. Immunotherapy for management of cancer

After radiotherapy, surgery or chemotherapy it has been observed that a small number of cancer cells may still remain alive and in addition to it the overall treatment quality is also decreased due to drug resistance. Immunotherapy has great potential to treat cancer as it acts on the immune system rather than on the tumor itself. Immunotherapy is considered as a unique and promising strategy for cancer therapy [60] and the main advantages include its specific promotion on immune cells only aiming on target cells or target tissues. So far, the related investigations have been gradually transformed from laboratory research to clinical practice. For clinical treatment the use of immunotherapeutic drugs such as immune checkpoint inhibitors and T cells have been approved by FDA and have great potential for cancer treatment. Improved immunotherapeutic nanomaterials loaded with antigens, immune adjuvants and nucleic acids have been demonstrated to be helpful. The nanoplatforms may affect and alter immune cell actions and response non-specifically. They may easily damage the cancer cells and achieve tumor targeting with pathogens factors. For e.g. repetitive and homogenous antigens conjugated with gold nanoparticles are able to trigger immune response in an in-vitro setting even without the use of adjuvant. Recently a combination of IR phthalocyanine dye IR700 with monoclonal antibodies had been fabricated and this novel technique is known as Photoimmunotherapy [61]. Least side effect and significantly fast cell necrosis rate is observed when antibodies bind to target tumor cells during the PIT and is activated by NIR light irradiation. Hence for monitoring and treating cancer in a highly selective manner PIT is a good theranostic approach.


10. Multimodal therapy for management of cancer

Conventional cancer therapies often do not succeed to eradicate tumor completely. In order to recover anticancer efficacy, the arrangement of two or more therapeutic modalities such as chemo photodynamic, photothermal photodynamic, chemo photo thermal synergistic formulations have been explored. Thermomotherapeutic characteristics in association with theranostic methods result in development of anticancer drug that possess synergistic therapeutic effect [62]. Chemotherapy could be improved by the use of photothermal effect which aids the intracellular translocation of anti-cancer drugs [63]. Risk of overtreatment could be minimized along with the reduction in dose of therapeutic agent with less laser exposure time. All these can be attained by combination of PDT/PTT. Synergistic effect of PTT/PDT have been seen when GO was loaded with methylene blue [64]. In this system, lesser dose of nano GO was applied, as compared to the particular PTT treatment of nano GO. In addition, the PTT and PDT combinational treatment could be spoil both superficial and deep regions of the tumor, and thus overcome the drawbacks of single treatments [65]. To further progress cancer therapy efficacy, numerous types of theranostic platforms were developed to combine chemotherapy, PTT and PDT simultaneously [66]. Treating cancer with combinational therapy has become an essential trend in cancer therapeutics. Compared to single modality therapy, the combined therapy can reduce the dosage of the drugs and thus decrease the side effects in treatment. More prominently, the combined therapy has the potential to decrease multidrug resistance of tumor cells, thus improving the therapeutic efficacy. The combined therapy may bring a novel opportunity to the next invention of cancer treatment [67].

11. Imaging-guided therapy for management of cancer

The theranostic nanoparticles have an ever increasing consideration for image guided therapy in current years because these nanoparticles can follow the pharmacokinetic process, guide the treatment and monitor therapeutic process and outcome. They could be employed to imagine and quantify the performance of drug delivery systems for numerous special purposes such as biodistribution and pharmacokinetics of nanocarriers, metabolic response and drug release process of the nanocarriers. Koukourakis group and Harrington group engaged Technetium and Indium labeled PEGylated liposomes respectively to monitor drug targeting to the sarcomas and breast cancer sites [69]. In the clinical practice, surgical resection is a regular and inevitable procedure for cancer therapy. Theranostics gives a possibility in intraoperative imaging to guide the operation process. During the surgery, physicians could congregate the diagnostic information for precise imaging as well as visualized therapy. In theranostic platform, DOTA-Gd act as a MRI contrast agent for preoperative finding and surgical planning; the Raman molecules visualized the excellent margin of tumor, allowing precise resection for the duration of operation process. The multimodal NP could recognize tumor edge for precise resection of tumor. This approach could be planned for simple intraoperative navigation and real-time imaging [70]. Theranostic technologies commonly utilized for cancer treatment are given in Table 2.

Imaging methodImaging agentTherapeutic agentFunction
Optical ImagingCy5.5PaclitaxelReal time tracking of NP location
FITC-coumarin pairDoxorubicinDrug release monitoring
Dicyanomethylene-4H-pyranCamptothecinDrug release monitoring
Cy7, 111InCyclophosphamide, etoposideReal time imaging of apoptosis
Cy5.5-BHQ pairDoxorubicinReal time imaging of apoptosis
Ce6Ce6Real time tracking of NP location & PDT
Ce6-BHQ pairCe6Drug release monitoring & PDT
UCNP (β-NaYF4:Yb3+,Er3+)Cisplatin prodrugImaging of NP location
UCNP (NaYF4:Er)TPGSdDual imaging (optical, CT) & reducing multidrug resistance
UCNP (NaYF4:Yb/Er)Ce6, doxorubicinImaging of particle location & chemotherapy/PDT
MR imagingGdDoxorubicinReal time monitoring of drug delivery
SPIONSPIONDetection & hyperthermia treatment of tumor
SPIONDoxorubicinTumor detection & chemotherapy
SPION/FITCsiRNAMR imaging & gene therapy
CT imagingGNPDoxorubicinCT imaging of cancer & chemotherapy
GNRGNRDual imaging (X-ray/CT) & PTT/radio sensitization
PET Imaging64CuDoxorubicinQuantitative biodistribution analysis & Chemotherapy
64CusiRNAQuantitative determination of biodistribution & efficacy of siRNA NPs
US imagingPerfluoropentaneDocetaxelTriggered drug release & chemotherapy
CaCO3DoxorubicinTumor imaging & triggered drug release
Perfluorooctyl bromideCamptothecinChemotherapy & ablation therapy
PerfluorohexaneCPT11mTumor imaging & chemotherapy/ablation Therapy

Table 2.

Theranostic technologies for cancer treatment [68].

12. Conclusion

Theranostic approach to management of cancer offers numerous advantages. They are designed to monitor cancer treatment in real time. A wide variety of theranostic nanoplatforms that are based on diverse nanostructures like magnetic nanoparticles, carbon nanotubes, gold nanomaterials, polymeric nanoparticles, or silica nanoparticles showed great potential as cancer theranostics. Nano therapeutic platforms have been successful in integrating image guidance with targeted approach to treat cancer.

Conflict of interest

Authors declare no conflict of interest related to this manuscript.


PTTPhotothermal therapy
PDTPhotodynamic therapy
NIRNear infrared
MRIMagnetic resonance imaging
PETPositron emission tomography
CTComputed topography
UNCPsUp converting nanoparticles
GOGrapheme oxide
MDRMultidrug resistance
MoS2Molybdenum disulfide
ICGIndocyanine green
WS2Tungsten disulfide
Ce6Chlorine e6


  1. 1. (last accessed on 01/08/2020)
  2. 2. McClements DJ. Nanoemulsions versus microemulsions: Terminology, differences, and similarities. Soft Matter. 2012;8(6):1719-1729
  3. 3. Ahmad, U., Akhtar, J., Singh, S.P., Badruddeen, Ahmad, F.J., Siddiqui, S. and Wahajuddin, 2017. Silymarin nanoemulsion against human hepatocellular carcinoma: development and optimization. Artificial cells, nanomedicine, and biotechnology, 46(2), pp.231-241
  4. 4. Shakeel F, Shafiq S, Haq N, Alanazi FK, Alsarra IA. Nanoemulsions as potential vehicles for transdermal and dermal delivery of hydrophobic compounds: An overview. Expert Opinion on Drug Delivery. 2012;9(8):953-974
  5. 5. Sarker DK. Engineering of nanoemulsions for drug delivery. Current Drug Delivery. 2005;2(4):297-310
  6. 6. Ali A, Ansari VA, Ahmad U, Akhtar J, Jahan A. Nanoemulsion: An advanced vehicle for efficient drug delivery. Drug research. 2017;67(11):617-631
  7. 7. Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Advanced Drug Delivery Reviews. 2008;60(6):757-767
  8. 8. Maali A, Mosavian MH. Preparation and application of nanoemulsions in the last decade (2000-2010). Journal of Dispersion Science and Technology. 2013 Jan 1;34(1):92-105
  9. 9. Chen XS. Introducing theranostics journal-from the editor-in-chief. Theranostics. 2011;1:1
  10. 10. Lukianova-Hleb EY, Oginsky AO, Samaniego AP, Shenefelt DL, Wagner DS, Hafner JH, et al. Tunableplasmonicnanoprobes for theranostics of prostate cancer. Theranostics. 2011;1:3
  11. 11. Zhu L, Xie J, Swierczewska M, Zhang F, Quan Q, Ma Y, et al. Real-time video imaging of protease expression in vivo. Theranostics. 2011;1:18
  12. 12. Fang C, Zhang M. Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine. Journal of Controlled Release: Official Journal of the Controlled Release Society. 2010;146(1):2
  13. 13. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discovery Today. 2012;17(17-18):928-934
  14. 14. Sumer, B. and Gao, J., 2008. Theranosticnanomedicine for Cancer
  15. 15. Bae KH, Lee K, Kim C, Park TG. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials. 2011;32(1):176-184
  16. 16. Huang P, Bao L, Zhang C, Lin J, Luo T, Yang D, et al. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials. 2011;32(36):9796-9809
  17. 17. Chen W, Bardhan R, Bartels M, Perez-Torres C, Pautler RG, Halas NJ, et al. A molecularly targeted theranostic probe for ovarian cancer. Molecular Cancer Therapeutics. 2010;9(4):1028-1038
  18. 18. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials. 2009;30(30):6065-6075
  19. 19. Lee JH, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. AngewandteChemie. 2009;121(23):4238-4243
  20. 20. Yang K, Zhang S, Zhang G, Sun X, Lee ST, Liu Z. Graphene in mice: Ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Letters. 2010;10(9):3318-3323
  21. 21. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials. 2011;32(29):7139-7150
  22. 22. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: A novel drug− carrier system for photodynamic therapy. Journal of the American Chemical Society. 2003;125(26):7860-7865
  23. 23. Park JH, Gu L, Von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nature Materials. 2009;8(4):331
  24. 24. Pantarotto D, Singh R, McCarthy D, Erhardt M, Briand JP, Prato M, et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. AngewandteChemie. 2004;116(39):5354-5358
  25. 25. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Research. 2008;68(16):6652-6660
  26. 26. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. Journal of Controlled Release. 2011;153(1):16-22
  27. 27. Li Z, Chen H, Bao H, Gao M. One-pot reaction to synthesize water-soluble magnetite nanocrystals. Chemistry of Materials. 2004;16(8):1391-1393
  28. 28. Souza KC, Salazar-Alvarez G, Ardisson JD, Macedo WAA, Sousa EMB. Mesoporous silica–magnetite nanocomposite synthesized by using a neutral surfactant. Nanotechnology. 2008;19(18):185603
  29. 29. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano;2(5):2008, 889-2896
  30. 30. Insin N, Tracy JB, Lee H, Zimmer JP, Westervelt RM, Bawendi MG. Incorporation of iron oxide nanoparticles and quantum dots into silica microspheres. ACS Nano. 2008;2(2):197-202
  31. 31. Kang L-J et al. Stabilization of superparamagnetic iron oxide core–gold shell nanoparticles in high ionic strength media. Langmuir. 2009;25:13384
  32. 32. Zhao N, Gao M. Magnetic janus particles prepared by a flame synthetic approach: Synthesis, characterizations and properties. Advanced Materials. 2009;21(2):184-187
  33. 33. Kamei K, Mukai Y, Kojima H, Yoshikawa T, Yoshikawa M, Kiyohara G, et al. Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery. Biomaterials. 2009;30(9):1809-1814
  34. 34. Wang L, Qiao H, Han J, Chen Y, Wang D, Li D. The mutual beneficial effect between medical imaging and nanomedicine. Journal of Nanomaterials. 2013;2013:5
  35. 35. Dai Y, Xiao H, Liu J, Yuan Q, Ma PA, Yang D, et al. In vivo multimodality imaging and cancer therapy by near-infrared light-triggered trans-platinum pro-drug-conjugated upconverison nanoparticles. Journal of the American Chemical Society. 2013;135(50):18920-18929
  36. 36. Chen F, Hong H, Zhang Y, Valdovinos HF, Shi S, Kwon GS, et al. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano. 2013;7(10):9027-9039
  37. 37. Wang CF, Sarparanta MP, Mäkilä EM, Hyvönen ML, Laakkonen PM, Salonen JJ, et al. Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials. 2015;48:108-118
  38. 38. Liu T, Wang C, Gu X, Gong H, Cheng L, Shi X, et al. Drug delivery with PEGylated MoS2 Nano-sheets for combined photothermal and chemotherapy of cancer. Advanced Materials. 2014;26(21):3433-3440
  39. 39. Zhang L, Xia J, Zhao Q, Liu L, Zhang Z. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small. 2010;6(4):537-544
  40. 40. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences. 2000;11(4):265-283
  41. 41. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews. 2012;64:24-36
  42. 42. Astier A, Doat B, Ferrer MJ, Benoit G, Fleury J, Rolland A, et al. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylatenanospheres, in U-937 cells. Cancer Research. 1988;48(7):1835-1841
  43. 43. Gobin AM, Lee MH, Halas NJ, James WD, Drezek RA, West JL. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Letters. 2007;7(7):1929-1934
  44. 44. Yang H, Mao H, Wan Z, Zhu A, Guo M, Li Y, et al. Micelles assembled with carbocyanine dyes for theranostic near-infrared fluorescent cancer imaging and photothermal therapy. Biomaterials. 2013;34(36):9124-9133
  45. 45. Yang K, Xu H, Cheng L, Sun C, Wang J, Liu Z. In vitro and in vivo near-infrared photothermal therapy of cancer using polypyrrole organic nanoparticles. Advanced Materials. 2012;24(41):5586-5592
  46. 46. Wang YW, Fu YY, Peng Q, Guo SS, Liu G, Li J, et al. Dye-enhanced graphene oxide for photothermal therapy and photoacoustic imaging. Journal of Materials Chemistry B. 2013;1(42):5762-5767
  47. 47. Tang J, Jiang X, Wang L, Zhang H, Hu Z, Liu Y, et al. Au@ Pt nanostructures: A novel photothermal conversion agent for cancer therapy. Nanoscale. 2014;6(7):3670-3678
  48. 48. Lin Z, Liu Y, Ma X, Hu S, Zhang J, Wu Q, et al. Photothermal ablation of bone metastasis of breast cancer using PEGylated multi-walled carbon nanotubes. Scientific Reports. 2015 Jun 30;5:11709
  49. 49. Tu X, Ma Y, Cao Y, Huang J, Zhang M, Zhang Z. PEGylated carbon nanoparticles for efficient in vitro photothermal cancer therapy. Journal of Materials Chemistry B. 2014;2(15):2184-2192
  50. 50. Yang K, Zhang S, Zhang G, Sun X, Lee ST, Liu Z. Graphene in mice: Ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Letters. 2010;10(9):3318-3323
  51. 51. Gupta AK, Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials. 2005;26(13):1565-1573
  52. 52. Mashal A, Sitharaman B, Li X, Avti PK, Sahakian AV, Booske JH, et al. Toward carbon-nanotube-based theranostic agents for microwave detection and treatment of breast cancer: Enhanced dielectric and heating response of tissue-mimicking materials. IEEE Transactions on Biomedical Engineering. 2010;57(8):1831-1834
  53. 53. Huang Z, Xu H, Meyers AD, Musani AI, Wang L, Tagg R, et al. Photodynamic therapy for treatment of solid tumors—Potential and technical challenges. Technology in Cancer Research & Treatment. 2008;7(4):309-320
  54. 54. Huang P, Lin J, Wang X, Wang Z, Zhang C, He M, et al. Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Advanced Materials. 2012;24(37):5104-5110
  55. 55. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. Chemical Reviews. 2015;115(4):1990-2042
  56. 56. Taratula O, Schumann C, Naleway MA, Pang AJ, Chon KJ, Taratula O. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Molecular Pharmaceutics. 2013;10(10):3946-3958
  57. 57. Li Z, Wang C, Cheng L, Gong H, Yin S, Gong Q, et al. PEG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted, NIR light induced, photodynamic therapy. Biomaterials. 2013;34(36):9160-9170
  58. 58. Park YI, Kim HM, Kim JH, Moon KC, Yoo B, Lee KT, et al. Theranostic probe based on lanthanide-doped nanoparticles for simultaneous in vivo dual-modal imaging and photodynamic therapy. Advanced Materials. 2012;24(42):5755-5761
  59. 59. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. Journal of Pharmacy and Pharmacology. 2008;60(8):977-985
  60. 60. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68
  61. 61. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared theranosticphotoimmunotherapy (PIT): Repeated exposure of light enhances the effect of immunoconjugate. Bioconjugate Chemistry. 2012;23(3):604-609
  62. 62. Zhang W, Wang Y, Sun X, Wang W, Chen L. Mesoporoustitania based yolk–shell nanoparticles as multifunctional theranostic platforms for SERS imaging and chemo-photothermal treatment. Nanoscale. 2014;6(23):14514-14522
  63. 63. Liu J, Wang C, Wang X, Wang X, Cheng L, Li Y, et al. Mesoporous silica coated single-walled carbon nanotubes as a multifunctional light-responsive platform for cancer combination therapy. Advanced Functional Materials. 2015;25(3):384-392
  64. 64. Sahu A, Choi WI, Lee JH, Tae G. Graphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapy. Biomaterials. 2013;34(26):6239-6248
  65. 65. Gong H, Dong Z, Liu Y, Yin S, Cheng L, Xi W, et al. Engineering of multifunctional nano-micelles for combined photothermal and photodynamic therapy under the guidance of multimodal imaging. Advanced Functional Materials. 2014;24(41):6492-6502
  66. 66. Taratula O, Schumann C, Duong T, Taylor KL, Taratula O. Dendrimer-encapsulated naphthalocyanine as a single agent-based theranosticnanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy. Nanoscale. 2015;7(9):3888-3902
  67. 67. Park H, Yang J, Lee J, Haam S, Choi IH, Yoo KH. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. ACS Nano. 2009;3(10):2919-2926
  68. 68. Jo SD, Ku SH, Won YY, Kim SH, Kwon IC. Targeted nanotheranostics for future personalized medicine: Recent progress in cancer therapy. Theranostics. 2016;6(9):1362
  69. 69. Koukourakis Sofia Koukouraki, Alexandra Giatromanolaki, SteliosKakolyris, VassilisGeorgoulias, AntigoniVelidaki, SpyridonArchimandritis and Nikolaos N. Karkavitsas, M.I., 2000. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: rationale for combination with radiotherapy. Actaoncologica, 39(2), pp.207-211
  70. 70. Kircher MF, De La Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, Mittra E, et al. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature Medicine. 2012;18(5):829

Written By

Asad Ali, Zeeshan Ahmad, Usama Ahmad, Mohd Muazzam Khan, Md. Faheem Haider and Juber Akhtar

Submitted: August 19th, 2020 Reviewed: October 8th, 2020 Published: October 27th, 2020